The project, titled “Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer’s disease,” is funded by the National Institute of Neurological Disorders and Stroke Innovation Grants to Nurture Initial Translational Efforts program, or IGNITE.
The project, titled “Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer’s disease,” is funded by the National Institute of Neurological Disorders and Stroke Innovation Grants to Nurture Initial Translational Efforts program, or IGNITE.
The Harrison College of Pharmacy s Raj Amin has received $1.1 million in support from the National Institutes of Health for the development of a compound that could help certain individuals who may be more susceptible to Alzheimer s disease at an earlier age.